Volume 64, Issue 1 pp. 95-99
CLINICAL RESEARCH SHORT REPORT

Buprenorphine may be effective for treatment of paramyotonia congenita

Sabrina Ravaglia MD, PhD

Corresponding Author

Sabrina Ravaglia MD, PhD

IRCCS Mondino Foundation, Pavia, Italy

Correspondence

Sabrina Ravaglia, IRCCS Mondino Foundation, Via Mondino 2, 27100 Pavia, Italy.

Email: [email protected]

Search for more papers by this author
Lorenzo Maggi MD

Lorenzo Maggi MD

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Search for more papers by this author
Antonio Zito MD

Antonio Zito MD

IRCCS Mondino Foundation, Pavia, Italy

Search for more papers by this author
Sebastiano Arceri MD

Sebastiano Arceri MD

IRCCS Mondino Foundation, Pavia, Italy

Search for more papers by this author
Pietro Gallotti MD

Pietro Gallotti MD

Istituto Clinico "Beato Matteo," Hospital Group San Donato, Vigevano, Italy

Search for more papers by this author
Concetta Altamura MD

Concetta Altamura MD

Sezione di Farmacologia, Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Università degli Studi di Bari Aldo Moro, Bari, Italy

Search for more papers by this author
Jean Francois Desaphy MD, PhD

Jean Francois Desaphy MD, PhD

Sezione di Farmacologia, Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Università degli Studi di Bari Aldo Moro, Bari, Italy

Search for more papers by this author
Pia Bernasconi MD

Pia Bernasconi MD

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Search for more papers by this author
Enrico Alfonsi MD

Enrico Alfonsi MD

IRCCS Mondino Foundation, Pavia, Italy

Search for more papers by this author
First published: 09 April 2021
Citations: 4

Sabrina Ravaglia and Lorenzo Maggi contributed equally to this study.

Abstract

Introduction/Aims

Paramyotonia congenita (PMC) is a skeletal muscle sodium channelopathy characterized by paradoxical myotonia, cold sensitivity, and exercise/cold-induced paralysis. Treatment with sodium-channel–blocking antiarrhythmic agents may expose patients to a risk of arrhythmia or may be poorly tolerated or ineffective. In this study we explored the effectiveness of non-antiarrhythmic sodium-channel blockers in two patients with PMC.

Methods

Earlier treatment with mexiletine was discontinued for gastrointestinal side effects in one of the patients and lack of clinical benefit in the other. One patient received lacosamide, ranolazine, and buprenorphine, and the other was given buprenorphine only. Drug efficacy was assessed by clinical scores, timed tests, and by long and short exercise tests.

Results

In both patients, buprenorphine improved pain scores by at least 50%, stiffness and weakness levels, and handgrip/eyelid-opening times. The fall in compound muscle action potential (CMAP) during short exercise normalized in both patients at baseline, and improved after cooling. During long exercise, one patient showed an earlier recovery of CMAP, and the other patient had a less severe decrease (<60%). With buprenorphine, the fall in CMAP induced by cooling normalized in one patient (from −72% to −4%) and improved (from −49% to −37%) in the other patient.

Discussion

Buprenorphine showed promising results for the treatment of exercise-induced paralysis and cold intolerance in the two patients assessed. The exercise test may be useful for quantitative assessment of treatment response. Further studies on a larger number of patients, under carefully controlled conditions, should be considered to address the effectiveness and long-term tolerability of this therapeutic option.

CONFLICT OF INTEREST

The authors declare no potential conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon request

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me